Adults 50 to 90, any sex, with Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Percentage of Adherence to Daily Device UsePrimary· Week 8
Feasibility of the Flicker intervention is defined as adherence to Flicker exposure, at home, for one hour per day for the duration of the intervention period (4 or 8 weeks). The percentages of completed sessions are presented here.
Group
Value
95% CI
Flicker/Flicker
95.55
± 2.92
No Flicker/Flicker
95.37
± 4.72
Percentage of Maximum Tolerated StimulationPrimary· Baseline
Participants rated their tolerance to Flicker stimulation prior to the study intervention, using a 1 - 5 point Likert scale for each of the 10 levels of brightness (visual stimulation) and each of the 10 levels of loudness (auditory stimulation) after 60 seconds of stimulation at each level. A rating of 1 indicated stimulation "can be withstood and comfortable," 3 indicated stimulation is "tolerable, but not necessarily comfortable," and 5 indicated stimulation "cannot be withstood or is uncomfortable." Ratings of 1, 2, and 3 were considered tolerable. After determining tolerance for auditory
Visual alone
Group
Value
95% CI
All Study Participants
94
± 9.66
Auditory alone
Group
Value
95% CI
All Study Participants
98
± 4.22
Visual when combined with auditory
Group
Value
95% CI
All Study Participants
93
± 12.52
Auditory when combined with visual
Group
Value
95% CI
All Study Participants
94
± 18.97
Adverse events — posted to ClinicalTrials.gov
Time frame: Adverse events were collected during the time when participants were receiving the Flicker intervention (up until Week 8 for the Flicker/Flicker group and until Week 4 for the No Flicker/Flicker group)..
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Flicker/Flicker
Serious: 0/5 (0%)
Deaths: 0/5
No Flicker/Flicker
Serious: 0/5 (0%)
Deaths: 0/5
Other adverse events (13 terms — click to expand)
Reaction
System
Flicker/Flicker
No Flicker/Flicker
Back pain
Musculoskeletal and connective tissue disorders
—
—
Dizziness
General disorders
—
—
Tinnitus
Ear and labyrinth disorders
—
—
Headache
General disorders
—
—
Double vision
General disorders
—
—
Leg, arm, joint pain
Musculoskeletal and connective tissue disorders
—
—
Depression
Psychiatric disorders
—
—
Rhinorrhea
General disorders
—
—
Gastrointestinal problems
General disorders
—
—
Fall
Injury, poisoning and procedural complications
—
—
Dog bite
Injury, poisoning and procedural complications
—
—
Skin growth on neck
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Alzheimer's disease is characterized by the accumulation of toxic proteins in the brain. Mechanisms to remove these proteins have been the target of many drug trials. This study is designed to use a device to entrain brain waves to a specific frequency to see if rodent research can be replicated in humans with mild cognitive impairment. Ten participants will be recruited from the Emory Alzheimer's Disease Research Center (ADRC) database and assigned to either treatment for 8 weeks or treatment for 4 weeks. This latter group will serve as the control group (4 weeks no treatment, 4 weeks treatment). It is hypothesized that exposure to the gamma oscillations (Flicker) will clear toxic proteins from the brain and increase cerebral blood flow.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07290387 — Tele-Savvy for Latino Caregivers
· NA
· recruiting
NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease
· NA
· recruiting
NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease
· NA
· recruiting
NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
· Phase 3
· recruiting
NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms
· NA
· recruiting
Other Emory University trials
Trials by the same sponsor.
NCT06143345 — HIIT in Isolated IFG: A Proof-of-Concept Study
· NA
· withdrawn
NCT07189819 — Innovative Closed-loop Functional Electrical Stimulation Control System for Augmenting Post-stroke Gait
· NA
· not yet recruiting
NCT06451055 — Low-calorie Diet in Isolated Impaired Fasting Glucose
· NA
· not yet recruiting
NCT07405476 — Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative I
· Phase 2
· recruiting
NCT06708351 — Enhancing Cervical Cancer Screening and Treatment in Women Living With HIV in Kenya, the ENHANCE LINKAge Trial
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Emory University
Last refreshed: 2 March 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03543878.